United Services Automobile Association Arrowhead Pharmaceuticals, Inc. Transaction History

United Services Automobile Association

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $38,360 - $55,567	-1,370 Reduced 11.7%	10,344 $419,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $12,800 - $20,869	432 Added 3.83%	11,714 $388,000
Q2 2022 Aug 16, 2022	BUY	$27.79 - $50.61 $313,526 - $570,982	11,282 New	11,282 $397,000
Q3 2019 Nov 13, 2019	SELL	$26.26 - $34.86 $538,723 - $715,152	-20,515 Closed	0 $0
Q2 2019 Aug 16, 2019	BUY	$17.43 - $28.82 $9,098 - $15,044	522 Added 2.61%	20,515 $544,000

Q1 2019 May 13, 2019	SELL	$12.05 - $20.18 $3,711 - $6,215	-308 Reduced 1.52%	19,993 $367,000
Q4 2018 Feb 13, 2019	BUY	$10.74 - $19.7 $2,835 - $5,200	264 Added 1.32%	20,301 $252,000
Q3 2018 Nov 13, 2018	BUY	$14.0 - $20.3 $13,916 - $20,178	994 Added 5.22%	20,037 $384,000
Q2 2018 Aug 10, 2018	BUY	$6.37 - $14.02 $49,787 - $109,580	7,816 Added 69.62%	19,043 $259,000
Q1 2018 May 14, 2018	BUY	$3.72 - $7.64 $41,764 - $85,774	11,227 New	11,227 $81,000

296

88.5M

905K

387K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.71B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of United Services Automobile Association, based on Form 13F filings with the SEC.

Stay updated on United Services Automobile Association with notifications on news.